Do Immunohistochemical Studies Have a Role in Predicting Prognosis of Laryngeal Squamous Cell Carcinomas? CD44 and Fascin Experience

Çiğdem Öztürk¹, Hüsnüye Esra Paşaoğlu², Funda Emre², Ümit Seza Tettik Kurt³, Tülin Şentürk Ege⁴

¹Recep Tayyip Erdogan University Training and Research Hospital, Pathology Department, Rize, Merkez, Rize, Turkey; ²University of Health Sciences Bagcılar Training and Research Hospital, Pathology Department, Istanbul, Turkey; ³Demiroğlu Bilim University Medical Faculty, Pathology Department, Istanbul, Turkey; ⁴University of Health Sciences Bagcılar Training and Research Hospital, Otolaryngology Department, Istanbul, Turkey

Abstract. Background and objectives: The diagnosis of laryngeal squamous cell carcinoma (LSCC) can be made easily based on histopathological findings, but the relationship between morphological findings and prognosis is not clear. In addition to morphological findings, the use of novel markers may contribute to the development of new treatment strategies and improved patient prognosis. CD44, which is a cancer stem cell marker, and Fascin-1, an actin-binding protein has been associated with poor prognosis in many tumors. The aim of this study was to investigate the relationship between CD44 and Fascin-1 expression and clinicopathologic parameters in LSCC and their roles in the determination of clinical behavior and prognosis. The aim of this study is to investigate whether CD44 and Fascin have a relationship with clinicopathological parameters and have a role in determining clinical behavior and prognosis in LSCC. Methods: 130 patients who were operated in our hospital for LSCC between 2012 and 2018 were included in this study. Fascin-1 and CD44 stains were applied immunohistochemically to the paraffin blocks of the tumors. Immunostained specimens were scored according to the intensity of staining and the percentage of staining for each marker. Overall scores were summed and was designated as immunoreactivity score (IRS). Finally, IRS was categorized into two groups; Low and High CD44/Fascin IRS. Results: There were no statistically significant differences between low and high CD44 and Fascin IRS groups in terms of clinicopathologic parameters, overall and disease-free survival (p > 0.05). Conclusion: Immunohistochemical studies are not yet sufficient to predict patient prognosis. Morphological findings still remain of priority and importance for pathologists. (www.actabiomedica.it)

Key words: Larynx, squamous cell carcinoma, CD44, Fascin

Introduction

Laryngeal squamous cell carcinoma (SCC) is the most common carcinoma of the respiratory system after lung carcinomas (1). While the diagnosis of laryngeal squamous cell carcinoma can be made easily based on histopathological findings, the relationship between morphological findings and prognosis is not clear (2).

Although significant improvements have been made in the surgical and radiotherapy techniques of laryngeal cancers, no significant change has been detected in the prognosis of the patients and the five-year life expectancy is approximately 60% (3).

In addition to morphological findings, various cytogenetic and molecular abnormalities have been shown to have prognostic significance (4). Using novel markers may contribute to the development of
new treatment strategies and improved patient prognosis (5). One of these, CD44, is a cancer stem cell marker (6). It is a surface adhesion molecule released from stem cells that program the properties of cancer cells such as regeneration, progression, invasion, local recurrence, resistance to chemotherapy, and radiotherapy (7). CD44 expression has been associated with tumor progression in many tumors (8).

Fascin-1 is an actin-binding protein that plays a role in many physiological functions of the cell and assists the cell motility in determining the risk of metastasis in many tumors (9). In laryngeal cancers, a positive correlation has been found between Fascin-1 expression and tumor grade, and lymph node metastasis in some studies (10).

The study aimed to investigate the relationship between CD44 and Fascin-1 expression and clinicopathological parameters in laryngeal squamous cell carcinoma and its role in the determination of clinical behavior and prognosis.

Materials and Methods

The surgical specimens of 130 patients who had undergone partial and total laryngectomy for laryngeal cancer in our hospital between 2012 and 2018 were included in the study.

Demographic characteristics, tumor localization, tumor diameter, cervical lymph node metastasis, total follow-up time, presence of recurrence, distant metastasis were obtained from the original pathology reports, and patient files. Moreover, missing information pertaining to the patients was filled through telephone interviews with patients themselves or their relatives.

We chose a representative block from each tumor for immunohistochemical analysis. A 2-mm section from each formalin-fixed, paraffin-embedded tumor tissue block which containing all morphological features of tumors was automatically immunostained using CD44 (Mouse monoclonal antibody, ready to use, Genetex) and Fascin (Mouse monoclonal antibody, FCN01-SSK2, ready to use, Thermo Scientific), using the avidin–biotin–peroxidase technique. The sections were incubated with the primary antibody at room temperature for 60 minutes.

Hodgkin lymphoma tissue for Fascin and tonsil tissue for CD44 were used as external control and also vascular endothelium for Fascin; inflammatory cells for CD44 were used as an internal control. The staining reaction was evaluated using a scoring system that was modified by Boxberg et al (21). Immunostained specimens were independently examined by two investigators and, in the instance of a discrepancy, by the third individual; the investigators were blinded to the origin of the specimen. Specimens were scored according to the intensity of staining (1, none to weak; 2, moderate; 3, strong) and the percentage of tumor cells stained (1, 0–5% positive; 2, 5–25% positive; 3, 25–50% positive; 4, 50–75% positive; 5, 75–100% positive) for each marker. Overall immunohistochemical scores for Fascin and CD44 expression were calculated for each case by summing the scores for staining intensity and percentage. This score was designated as an immunoreactivity score (IRS). Possible IRS ranged from 2 to 8. Finally, we categorized the IRS into two groups; 4 and below: low CD44/Fascin IRS and over 4: high CD44/Fascin IRS.

CD44/ Fascin IRS was compared according to following parameters: Age, sex, localization, tumor diameter, histological grade, lymph node metastasis, clinical stage and overall survival and disease-free survival of the cases.

In this study, statistical analysis was performed by NCSS (Number Cruncher Statistical System) 2007 Statistical Software (Utah, USA). Descriptive statistical methods (frequency and percentage distributions) were used to evaluate the data, and the chi-square test was used to compare qualitative data. Survival analysis of CD44, Fascin IRS groups were evaluated by Kaplan Meier and Log-Rank test. The results were evaluated with a significance level of $p < 0.05$ and a 95% confidence interval.

Results

Of the 130 patients, 128 were male (98.46%) and 2 were female (6.2%). The ages of the patients ranged from 42 to 89 years. 42 cases (32.31%) were supraglottic, 42 cases (32.31%) were glottic, 1 case subglottic (0.77%), 45 cases (34.46%) were in transglottic location.
Cervical lymph node metastasis was present in 48 (36.92%) of the cases. Extracapsular dissemination was seen in 27 (54.00%) of the patients with neck metastasis. The patients had a follow-up period of 12–86 months and 90 (69.23%) of the patients were alive without recurrence or metastasis at the time of statistical analysis, 13 (10.00%) survived with relapse or metastasis, 20 (15%) 38) patient died because of cancer; 7 patients (5.38%) died because of other reasons.

90 (69.23%) of the cases were keratinized type SCC, 26 (20.00%) were nonkeratinized type SCC and 14 (10.77%) were basaloid type SCC. The majority of the cases were evaluated as Grade 2 (91, 70.00%), 22 cases (16.92%) as Grade1, and 17 cases (13.08%) as Grade 3 according to WHO criteria. There was no significant difference in age and gender between the low and high CD44/Fascin IRS groups. (p > 0.05). According to the WHO grading system, no statistically significant difference was observed between the groups (p > 0.05). There was no statistically significant relationship between tumor localization, histological subtypes, lymph node metastasis, T and N stage, and CD44/Fascin IRS groups. (p > 0.05).

There was also no statistically significant difference between CD44 / Fascin IRS low and high groups in terms of lymphovascular and perineural invasion, presence of necrosis, amount of stroma, and lymphocytic response accompanying tumor (p > 0.05) (Table 1,2).

Table 1. Clinicopathological variables by overall CD44 expression score

|                  | ≤4 CD44 n:59 | >4 CD44 n:71 | P     |
|------------------|--------------|--------------|-------|
| Age              |              |              |       |
| <65              | 42           | 71.19%       | 49    | 69.01% | 0.788  |
| >65              | 17           | 28.81%       | 22    | 30.99% |        |
| Sex              |              |              |       |
| Female           | 1            | 1.69%        | 1     | 1.41%  | 0.895  |
| Male             | 58           | 98.31%       | 70    | 98.59% |        |
| Localization     |              |              |       |
| Supraglottic     | 17           | 28.81%       | 25    | 35.21% | 0.778  |
| Glottic          | 20           | 33.90%       | 22    | 30.99% |        |
| Subglottic       | 1            | 1.69%        | 0     | 0.00%  |        |
| Transglottic     | 17           | 28.81%       | 20    | 28.17% |        |
| Glotic+Subglottic| 4            | 6.78%        | 4     | 5.63%  |        |
| WHO Grade        |              |              |       |
| Grade 1          | 11           | 18.64%       | 11    | 15.49% | 0.635  |
| Grade 2          | 42           | 71.19%       | 49    | 69.01% |        |
| Grade 3          | 6            | 10.17%       | 11    | 15.49% |        |
| T Stage          |              |              |       |
| T1               | 6            | 10.17%       | 4     | 5.63%  | 0.279  |
| T2               | 31           | 52.54%       | 39    | 54.93% |        |
| T3               | 20           | 33.90%       | 20    | 28.17% |        |
| T4               | 2            | 3.39%        | 8     | 11.27% |        |
| N Stage          |              |              |       |
| N0               | 35           | 59.32%       | 47    | 66.20% | 0.538  |
| N1               | 5            | 8.47%        | 4     | 5.63%  |        |
| N2               | 6            | 10.17%       | 10    | 14.08% |        |
| N3               | 13           | 22.03%       | 10    | 14.08% |        |
| AJCC Stage       |              |              |       |
| Stage 1          | 5            | 8.47%        | 4     | 5.63%  | 0.397  |
| Stage 2          | 17           | 28.81%       | 27    | 38.03% |        |
| Stage 3          | 17           | 28.81%       | 16    | 22.54% |        |
| Stage 4a         | 7            | 11.86%       | 14    | 19.72% |        |
| Stage 4b         | 13           | 22.03%       | 10    | 14.08% |        |

(continued)
### Table 2. Clinicopathological variables by overall Fascin expression score

| Variable                        | \(\leq 4\) Fascin n:39 | >4 Fascin n:71 | P     |
|---------------------------------|------------------------|----------------|-------|
| **Age**                         |                        |                |       |
| <65                             | 2955.546 pt            | 62             | 68.13%| 0.478|
| >65                             | 10                     | 29             | 31.87%|       |
| **Sex**                         |                        |                |       |
| Female                          | 1                      | 1              | 1.10% | 0.534|
| Male                            | 38                     | 90             | 98.90%|       |
| **Localisation**                |                        |                |       |
| Supraglottic                    | 10                     | 32             | 35.16%| 0.127|
| Glottic                         | 12                     | 30             | 32.97%|       |
| Subglottic                      | 1                      | 0              | 0.00% |       |
| Transglottic                    | 11                     | 26             | 28.57%|       |
| Glottic + Subglottic            | 5                      | 3              | 3.30% |       |
| **WHO Grade**                   |                        |                |       |
| Grade 1                         | 8                      | 14             | 15.38%| 0.681|
| Grade 2                         | 27                     | 64             | 70.33%|       |
| Grade 3                         | 4                      | 13             | 14.29%|       |
| **T Stage**                     |                        |                |       |
| T1                              | 3                      | 7              | 7.69% | 0.980|
| T2                              | 20                     | 50             | 54.95%|       |
| T3                              | 13                     | 27             | 29.67%|       |
| T4                              | 3                      | 7              | 7.69% |       |
| **N Stage**                     |                        |                |       |
| N0                              | 25                     | 57             | 62.64%| 0.736|
| N1                              | 3                      | 6              | 6.59% |       |
| N2                              | 3                      | 13             | 14.29%|       |
| N3                              | 8                      | 15             | 16.48%|       |
| **Lymphovascular invasion**     |                        |                |       |
| No                              | 23                     | 57             | 62.64%| 0.694|
| Yes                             | 16                     | 34             | 37.36%|       |
| **Perineural invasion**         |                        |                |       |
| No                              | 35                     | 76             | 83.52%| 0.357|
| Yes                             | 4                      | 15             | 16.48%|       |

Chi-square test
Figure 3. High intensity and prevalence of CD44 immunoreactivity in the tumor (CD44 x40).

Figure 4. CD44 immunoreactivity with moderate intensity and prevalence in the tumor (CD44 x100).

Chi-Square Test

In some of the cases, more intense staining with CD44 was observed on the invasive margin (Figure 1, 2). The pictures showing staining with CD44 and Fascin of the cases are shown in figures 3-8.
Relationship between CD44 expression and survival of patients

The 5-year disease-free survival of the CD44-IRS-low group was found to be 65.11–80.29%, and the 5-year disease-free survival of the CD44-IRS-high group was 63.57–77.27%. Additionally, the 5-year overall survival of the low CD44 IRS group was found to be 64.41–80.12%, the 5-year overall survival of the high CD44 IRS group was 62.65–76.92% and no statistically significant difference was observed between the survival time of the groups (p > 0.05). The survival curve of the cases is shown in Figures 9 and 10.

Relationship between CD44 expression and survival

The 5-year disease-free survival of the low Fascin IRS group was 63.29–83.03%, and the 5-year disease-free survival of the high Fascin IRS group was 63.39–75.79%. In addition, the 5-year average survival rate of the low Fascin IRS group was 64.48–83.23%, and the 5-year average survival rate of the high Fascin IRS group was 64.33–76.21%. (>0.05). Disease-free and general survival curves of the cases are shown in Figures 11 and 12.

Discussion

Laryngeal squamous cell carcinoma (SCC) is the most common carcinoma of the respiratory system
Figure 9. Overall survival curve of CD44 IRS groups (Kaplan Meier, p > 0.05).

Figure 10. Disease-free survival curve of CD44 IRS groups (Kaplan Meier, p > 0.05).
Figure 11. Overall survival curve of Fascin IRS groups (Kaplan Meier, p > 0.05).

Figure 12. Disease-free survival curve of Fascin IRS groups (Kaplan Meier, p > 0.05).
Acta Biomed 2021; Vol. 92, N. 6: e2021309

and clinicopathologic factors in oral SCCs. They found a significant association between CD44 expression and tumor budding, small tumor cell nest, and poor differentiation (21).

In this study, CD44 expression was evaluated separately in the main tumor mass and invasive margins of the tumor; CD44 expression in the main tumor mass was associated with poor prognosis, whereas CD44 expression at the invasive margin was not associated with prognosis.

In our study, CD44 expression was evaluated by grouping it as low and high according to the immunoreactivity score (IRS) based on the percentage and intensity of staining in the main mass of the tumor.

In contrast to studies in the literature that high CD44 expression is associated with poor prognosis, there are also studies suggesting that low CD44 expression is associated with poor prognosis in different localizations of the head and neck (6, 7, 22–24). And also, in some studies, no correlation was found between CD44 expression and prognosis (20). In our study, no correlation was found between CD44 expression and overall and disease-free survival of the patients.

Due to conflicting results in the literature, the relationship between CD44 expression and prognosis should be reviewed with new comprehensive studies consisting of a higher number of patients.

Fascin is an actin-binding protein, involved in cell motility which was first detected in 1970 (25). There are many studies in the literature on whether to use it as a biomarker to predict the behavior of the tumor and guide its treatment.
In a review study by Hashimoto et al. investigating the role of Fascin in human cancer cells, it was reported that Fascin is not only released from malignant cells but also from healthy epithelial cells. Thus it has been suggested that Fascin expression has a limited place in targeted therapies, yet it may detect early stages of the aggressive clinical course of tumors (26).

In the literature, Jawhari et al. found that cells that express the Fascin molecule at a higher rate had higher adhesion ability and showed more invasive properties in colonic cancer cells, in vitro (27). Cao et al. investigated the relationship between expression of 15 cell skeletal proteins, including Fascin, and patients’ survival in esophageal SCCs. They found that Fascin molecule alone was not significant in patient survival. In the same study, the use of all proteins that made up the cell skeleton as a cocktail had been found to yield significant results in the determination of prognosis (24). There are other studies in the literature in which Fascin expression alone does not produce significant results (28). Therefore, the use of Fascin protein in combination with other proteins that play a role in the cell skeleton, may give more beneficial results.

Zhang et al. examined the distribution of Fascin expression between normal epithelium, hyperplastic epithelium, atypical hyperplasia, carcinoma in situ and invasive carcinoma; They found that Fascin expression increased because of proliferative activity of the cell. They suggested that increased Fascin expression in progression from normal epithelium to invasive carcinoma may be valuable in recognizing early stage esophageal SCC. However, no significant association was found between Fascin expression and prognostic parameters in the same study (29). Conversely to the study of Zhang et al., studies are suggest that increased Fascin expression levels correlate with tumor grade, stage and metastasis and poor prognosis in esophageal, non-small cell lung carcinomas, breast, colon, ovarian, pancreatic and prostate cancers (27, 30, 31).

Durmaz et al. evaluated Fascin expression in a group of 30 patients with laryngeal SCC and found that patients with high Fascin expression had a worse prognosis and they concluded that Fascin expression increased as the T, N, clinical-stage increased (32). In our study, no statistically significant difference was found between pT1, pT2, pT3, pT4 stages in terms of Fascin expression. This result contradicts with the findings of Durmaz et al. Such a discrepancy may arise from the fact that their study conducted using a smaller sample of patients.

In a study of 216 patients, Gao et al. found that Fascin, Ezrin and Paxillin immunohistochemical expression correlates with advanced stage (pT3, pT4), poor differentiation, lymph node involvement, and advanced clinical stages (III, IV) (10). In our study, no statistically significant difference was found between Fascin expression and pT, pN stage, and differentiation.

The reason that our findings do not correspond to the study of Gao et al. may be due to the tendency of our cases to cluster into the early stages. More reliable results can be achieved with larger case series representing all stages. Gao et al. also observed more Fascin expression in patients with supraglottic localized laryngeal SCC than glottic involvement. In our study, Fascin IRS was found to be high in 32 of 42 supraglottic laryngeal SCC cases. Similarly, Fascin IRS was found to be high in 30 of 42 glottic cases. Laryngeal SCC is seen in different localizations in different geographical regions. Therefore, whether Fascin expression varies by localization should be supported by new multicenter data. Furthermore, since lymphatic drainage of the larynx differs according to localization, it may be more appropriate to compare tumors in the same location for reliable results.

Papaspyrou et al. found no significant relationship between Fascin expression and pT stage, pM stage, sex, localization, disease-free survival, and overall survival in oropharynx SCCs however, they found that Fascin expression was associated with the pN stage of patients (33).

In our study, no significant correlation was found between Fascin expression and age, sex, localization, pT, pN, pM stages of the patients.

Zou et al. find that Fascin and E-cadherin expression was associated with the pT stage, lymph node metastasis, and histologic grade in patients with laryngeal SCC (34).

In our study, Fascin IRS was found to be high in 34 of 48 patients with cervical metastasis, but this finding was not statistically significant. In addition, there was no significant association between WHO grade groups and Fascin IRS low and high groups. This may
be due to the clustering of our cases in grade 2 and the low reproducibility of the WHO grading system among pathologists.

Few studies investigate the relationship between Fascin expression and other parameters that may have a role in prognoses such as lymphovascular invasion, perineural invasion, necrosis, tumor stroma ratio and tumor accompanying lymphocyte infiltration. In our study, the relationship between these parameters and fascin expression was investigated, but no significant result was obtained.

Conclusion

The WHO grading system currently used in laryngeal carcinomas is based on subjective criteria and has low reproducibility among pathologists. Therefore, it is necessary to look for a new marker or morphological finding in prognosis estimation. In our study, CD44 and Fascin expression were not associated with prognosis. In conclusion, immunohistochemical studies may not be useful in predicting prognosis; morphological findings remain of priority and importance for pathologists.

New and comprehensive immunohistochemical and molecular studies are needed to find new markers that may be effective in predicting prognosis and treatment management.

Conflicts of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.

Acknowledgment: This study was the thesis named “The evaluation of Fascin-1 and CD44 expression in laryngeal squamous cell carcinomas, predictive and prognostic importance” and we are thankful to the University of Health Sciences Bagcilar Training and Research Hospital for supporting our study.

References

1. Cattaruzza MS, Maisonneuve P, Boyle P. Epidemiology of laryngeal cancer. Eur J Cancer B Oral Oncol. 1996;32B(5):293–305.
2. Stelow BE. The Larynx, Sternberg’s Diagnostic Surgical Pathology, 6th editio. Stacey ME, New York, Lippincott Williams and Wilkins 2015: 903–928.
3. Huang Q, Yu GP, McCormick SA, et al. Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression. Genes Chromosomes Cancer. 2002;34(2):224–233.
4. Trapasso S, Allegra E. Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biologics. 2012;6:379–383.
5. Sun S, Pan X, Zhao L, Zhou J, Wang H, Sun Y. The Expression and Relationship of CD68-Tumor-Associated Macrophages and Microvascular Density With the Prognosis of Patients With Laryngeal Squamous Cell Carcinoma. Clin Exp Otorhinolaryngol. 2016;9(3):270–277.
6. Kokko LL, Hurme S, Maula SM, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 2011;47(6):510–516.
7. Esteban F, Bravo JJ, González-Moles MA, Bravo M, Ruiz-Avila I, Gil-Montoya JA. Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res. 2005;25(2A):1115-1121.
8. Yan Y, Zuo X, Wei D. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target. Stem Cells Transl Med. 2015;4(9):1033-1043.
9. Du ZP, Wu BL, Xie JJ, et al. Network Analyses of Gene Expression following Fascin Knockdown in Esophageal Squamous Cell Carcinoma Cells. Asian Pac J Cancer Prev. 2015;16(13):5445–5451.
10. Gao W, Zhang C, Feng Y, et al. Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma. PLoS One. 2012;7(11):e50710.
11. Slootweg GJR. Tumours of the hypopharynx, larynx, trachea and parathyroidal tissue. WHO Classification of Head and Neck. 4th editio., SP Naggar AK, Chan J, Grandis J, Takata T, Lyon, IARC Press, 2017; 8–104.
12. Broders AC. Squamous cell epithelioma of the lip. J Am Med Assoc. 1920;74:656–664.
13. Bryne M, Jensen N, Boysen M. Histological grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. Virchows Arch. 1995;427(3):277–281.
14. Wierink G, Millard PR, Haybittle JL. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology. 1991;19(5):411–417.
15. Almangush A, Bello IO, Keski-Säntti H, et al. Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early-stage oral tongue cancer. Head Neck. 2014;36(6):811–818.
16. Perez-Ordoñez B, Beuchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006;59(5):445–453.
17. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer. 2011;11(4):254–267.
18. Bartakova A, Michalova K, Presl J, Vlasak P, Kostun J, Bouda J. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma. J Obstet Gynaecol. 2018;38(1):110–114.
19. Nam KH, Yoon H, Lee K, et al. Predictive value for lymph node metastasis of epithelial-mesenchymal transition and cancer stem cell marker expression in early gastric cancer. Pathol Res Pract. 2017;213(9):1221–1226.
20. Krump M, Ehrmann J. Differences in CD44s expression in HNSCC tumours of different areas within the oral cavity. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(4):280–283.
21. Boxberg M, Götz C, Haidari S, et al. Immunohistochemical expression of CD44 in oral squamous cell carcinoma in relation to histomorphological parameters and clinicopathological factors. Histopathology. 2018;73(4):559–572.
22. Güler G, Saraç S, Uner A, Karabulut E, Ayhan A, Hiroshi O. Prognostic value of CD44 variant 6 in laryngeal epidermoid carcinomas. Arch Otolaryngol Head Neck Surg. 2002;128(4):393–397.
23. de Jong MC, Pramana J, van der Wal JE, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res. 2010;16(21):5329–5338.
24. Cão HH, Zhang SY, Shen JH, et al. A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget. 2015;6(7):5435–5448.
25. Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC. Fascins, and their roles in cell structure and function. Bioessays. 2002;24(4):350–361.
26. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?. Int J Biochem Cell Biol. 2005;37(9):1787–1804.
27. Jawhari AU, Buda A, Jenkins M, et al. Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol. 2003;162(1):69–80.
28. Roseweir AK, Kong CY, Park JH, et al. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. Int J Cancer. 2019;144(1):150–159.
29. Zhang H, Xu L, Xiao D, et al. Fascin is a potential biomarker for early-stage esophagel squamous cell carcinoma. J Clin Pathol. 2006;59(9):958–964.
30. Chen WX, Hong XB, Hong CQ, et al. Tumor-associated autoantibodies against Fascin as a novel diagnostic biomarker for esophageal squamous cell carcinoma. Clin Res Hepatol Gastroenterol. 2017;41(3):327–332.
31. Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, et al. Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma. Oncotarget. 2017;8(43):74736–74754.
32. Durmaz A, Kurt B, Ongoru O, Karahatay S, Gerek M, Yalcin S. Significance of fascin expression in laryngeal squamous cell carcinoma. J Laryngol Otol. 2010;124(2):194–198.
33. Papaspyrou K, Brochhausen C, Schmidtmann I, et al. Fascin upregulation in primary head and neck squamous cell carcinoma is associated with lymphatic metastasis. Oncol Lett. 2014;7(6):2041–2046.
34. Zou J, Yang H, Chen F, et al. Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev. 2010;19(1):11–17.